uniQure

$46.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (+0.11%) Today
$0.00 (0.00%) As of 6:00 PM EST after-hours

Why Robinhood?

You can buy or sell uniQure and other stocks, options, and ETFs commission-free!

About QURE

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands. The listed name for QURE is uniQure N.V. Ordinary Shares.

CEO
Matthew C. Kapusta
Employees
248
Headquarters
Amsterdam, Noord-Holland
Founded
1998
Market Cap
2.07B
Price-Earnings Ratio
Dividend Yield
Average Volume
483.78K
High Today
$46.95
Low Today
$45.89
Open Price
$45.89
Volume
234.30K
52 Week High
$76.69
52 Week Low
$34.38

Collections

QURE Earnings

-$1.21
-$0.81
-$0.40
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 1, Pre-Market

You May Also Like